| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Aristolone inhibits the C1 complement component. It induces mesenteric vasodilation and ameliorates hypertension via activation of the KATP channel and PDK1-Akt-eNOS pathway. It also has DNA damaging activity.
|
|---|---|
| ln Vitro |
In cell-free systems, Aristolone's activity is assessed by its ability to inhibit the C1 complement component. This can be measured in assays that evaluate the complement pathway. Its DNA damaging activity can be tested using DNA repair-deficient yeast mutants. In vitro, Aristolone produces cytotoxic effects on cells. It induces apoptosis in HeLa cells. It has been studied for its anticancer properties, particularly in cervical cancer research. It is known for its cytotoxic effects on cancer cells.
|
| ln Vivo |
Aristolone has been shown to induce mesenteric vasodilation and ameliorate hypertension in vivo via activation of the KATP channel and PDK1-Akt-eNOS pathway. This suggests potential cardiovascular effects. It exhibits DNA damaging activity.
|
| Enzyme Assay |
In vitro, the inhibition of the C1 complement component by Aristolone can be measured in a cell-free assay using purified complement proteins. The compound's ability to prevent complement-mediated lysis is quantified. Its DNA damaging activity is assessed using a yeast mutant system.
|
| Cell Assay |
Cells, such as HeLa cervical cancer cells, are treated with Aristolone. Cell viability is measured using assays like MTT. Apoptosis is assessed by flow cytometry using Annexin V staining. Cytotoxicity is evaluated by measuring LDH release.
|
| Animal Protocol |
Aristolone's vasodilatory and antihypertensive effects are studied in animal models. Blood pressure is measured, and mesenteric artery diameter is assessed. Its anticancer activity may be evaluated in tumor xenograft models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Aristolone are not well-documented. As a sesquiterpene, its oral bioavailability and metabolic stability are unknown. Further studies are needed to characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for Aristolone is limited. Its cytotoxic effects on cells suggest it may have a narrow therapeutic window. Its safety profile requires further investigation, especially if it is to be developed as a therapeutic agent.
|
| Additional Infomation |
Aristolochicone has been reported to have been found in Chlamydomonas amygdalina, Cryptocytoplasma amygdalina, and other organisms for which data is available.
Aristolone is a research compound with potential anticancer and cardiovascular activities. It is a valuable tool for studying the complement system and vascular biology. It is not an approved drug and is for research use only. |
| Molecular Formula |
C15H22O
|
|---|---|
| Molecular Weight |
218.3346
|
| Exact Mass |
218.167
|
| CAS # |
25274-27-5
|
| PubChem CID |
165536
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
308.7±9.0 °C at 760 mmHg
|
| Flash Point |
136.5±9.6 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.525
|
| LogP |
3.89
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
16
|
| Complexity |
390
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C[C@@H]1CCCC2=CC(=O)[C@@H]3[C@H]([C@@]12C)C3(C)C
|
| InChi Key |
UGVIZCBJCSXBCJ-JWFUOXDNSA-N
|
| InChi Code |
InChI=1S/C15H22O/c1-9-6-5-7-10-8-11(16)12-13(14(12,2)3)15(9,10)4/h8-9,12-13H,5-7H2,1-4H3/t9-,12-,13+,15+/m1/s1
|
| Chemical Name |
(1aR,7R,7aR,7bS)-1,1,7,7a-tetramethyl-1a,4,5,6,7,7b-hexahydrocyclopropa[a]naphthalen-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~83.33 mg/mL (~381.67 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 6.25 mg/mL (28.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 6.25 mg/mL (28.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 62.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 6.25 mg/mL (28.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.5802 mL | 22.9011 mL | 45.8022 mL | |
| 5 mM | 0.9160 mL | 4.5802 mL | 9.1604 mL | |
| 10 mM | 0.4580 mL | 2.2901 mL | 4.5802 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
